Today: 30 June 2026
Browse Category

NYSE:NVO 23 December 2025 - 6 January 2026

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.
5 January 2026
·····
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk said it is lowering prices of its top-selling obesity drug Wegovy in China, after local outlet Yicai reported that list prices for the two highest doses were cut by 48% in the southwestern provinces of Yunnan and Sichuan. The new monthly list prices were 987 yuan and 1,284 yuan, Yicai said, citing local procurement authorities. Reuters The price move matters because China is fast becoming a pivotal growth market for weight-loss medicines, and pricing is now moving to the center of competition. Drugmakers are trying to lock in patients and set benchmarks before cheaper alternatives arrive.
30 December 2025
·
Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

December 25, 2025 — Christmas Day is a market holiday in the U.S., but Novo Nordisk A/S is still doing what it’s done for most of the past two years: pulling attention toward anything labeled GLP‑1. NASDAQ Trader The headline catalyst is straightforward and extremely investable: the U.S. FDA has approved Novo Nordisk’s Wegovy pill, making it the first oral GLP‑1 treatment approved for chronic weight management in adults with obesity. Reuters
25 December 2025
·
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly and Company stock is in the spotlight on December 24, 2025 as investors digest a new round of GLP‑1 headlines that span regulatory momentum, global market expansion, and shifting coverage expectations—all of which feed directly into the long-term demand outlook for Lilly’s obesity and diabetes franchise. In a shortened U.S. trading session—with NYSE and Nasdaq closing early at 1:00 p.m. ET—LLY shares traded modestly higher in morning action, with lighter volume typical of holiday weeks. New York Stock Exchange+1
24 December 2025
···
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Dec. 24, 2025 — Novo Nordisk A/S has snapped back into the market’s spotlight this week after U.S. regulators cleared a pill version of its blockbuster obesity drug Wegovy—an approval that investors and analysts see as a pivotal moment in the fast-evolving GLP‑1 weight-loss race. But the story driving Novo Nordisk stock today is bigger than a single FDA decision: it’s also about pricing and coverage policy in the U.S., and a global expansion battle—especially in India—where branded GLP‑1s are colliding with the prospect of cheaper generics in 2026. Novo Nordisk+2Reuters+2 NVO shares have been trading around the low-$50s in U.S. action around Christmas Eve, after a sharp pop earlier in the week tied to the FDA decision and follow-on “what does this mean for 2026?” positioning. MarketWatch+2Investing.com Nigeria+2
24 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly and Company ended Tuesday, December 23, 2025, modestly lower as investors digested a major competitive jolt in the booming obesity-drug market. LLY closed at $1,071.64, down about 0.45%, and was little changed in early after-hours trading. FinancialContent+1 The market’s attention today wasn’t on a fresh Lilly press release or an earnings surprise—it was on Novo Nordisk’s newly approved Wegovy pill, the first oral GLP‑1 cleared in the U.S. for chronic weight management. That approval, announced Monday and dominating headlines today, is reshaping near-term expectations for how the next phase of the GLP‑1 race will be fought: pills, pricing, and access. Reuters+2Reuters+2
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

December 23, 2025 — Eli Lilly and Company stock is holding near record territory as investors digest a fresh twist in the weight-loss drug race: the FDA has cleared Novo Nordisk’s first oral version of Wegovy, intensifying competition right as Lilly pushes its own once-daily pill candidate, orforglipron, toward a potential 2026 approval. As of 15:11 UTC on Tuesday, LLY traded around $1,077, slightly above the prior close, after moving between roughly $1,057 and $1,088 during the session.
23 December 2025
···
Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

December 23, 2025 — Novo Nordisk A/S is back in the spotlight after U.S. regulators approved a pill version of Wegovy, a milestone that could reshape the fast-growing obesity drug market—and potentially reset the narrative around a stock that’s had a bruising 2025. In U.S. trading on Dec. 23, Novo Nordisk shares traded around $52, up roughly 9% on the day, as investors digested what the approval means for market share, pricing power, and the competitive race with Eli Lilly. Reuters
23 December 2025
·
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

December 23, 2025 — Eli Lilly and Company is trading around $1,076 as investors digest a fresh competitive jolt in the obesity-drug race: the FDA has approved Novo Nordisk’s first daily oral version of Wegovy. The headline is about Novo, but the market’s real question is about Lilly’s moat: can LLY keep dominating the category while a new “pill era” starts to form? Reuters+1 On December 23, Novo Nordisk won U.S. approval for a 25 mg oral Wegovy pill for chronic weight management—positioning Novo as first-to-market in highly effective oral obesity therapy. Novo has said it expects a U.S. launch in January 2026, leaning heavily into access through large pharmacies and cash-pay pathways. Reuters+2Reuters+2
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk A/S is back in the market’s spotlight on 23 December 2025 after a major regulatory milestone: the U.S. Food and Drug Administration approved a pill version of Wegovy, making it the first oral GLP‑1 receptor agonist cleared for chronic weight management in the U.S. The news sent Novo Nordisk shares sharply higher in early trading and reverberated across European markets, where the company’s move helped lift healthcare stocks. Novo Nordisk+2Reuters+2 The approval also lands at a delicate moment for Novo: competition from Eli Lilly has intensified, pricing pressure is building, and investors have been scrutinizing Novo’s growth outlook and execution. Today’s FDA decision doesn’t erase those issues—but it changes the chessboard for 2026. Reuters+1
23 December 2025
···
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk+1 For Novo Nordisk, the milestone is more than a product expansion. It’s a high‑stakes move to defend its GLP‑1 franchise, widen access beyond injections, and reassert momentum after a volatile year in which investors questioned its growth trajectory and competitive positioning. Reuters+1
23 December 2025
··
Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly and Company ended Monday’s regular session higher — then slipped after the closing bell as investors digested a major late-day headline from its biggest obesity rival, Novo Nordisk. LLY closed at $1,076.48 at 4:00 p.m. ET on Monday, Dec. 22, 2025, then traded down about 1% in after-hours action, around $1,065.50 as of 6:18 p.m. ET. StockAnalysis+1
23 December 2025
····
1 2 3 4 5 6 7

Stock Market Today

  • Sage Group Target Cut to £10.79 as Analysts Disagree on Growth Path
    June 30, 2026, 9:12 AM EDT. The fair value target for Sage Group (LSE:SGE) is lowered to £10.79 from £11.40, down 5%. Analyst price targets are split, going from 900 GBp at Deutsche Bank up to 1,165 GBp at Peel Hunt, showing disagreement on growth and valuation. Revenue growth forecast dips to 8.54%. Net margin is now seen at 17.40%. Sage's forward P/E gets cut to 20.56x. Bulls point to Sage's AI products and expansion, while others stay cautious. Investors watching for more on Sage's new products and strategy.
Go toTop